BioNTech (BNTX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

$1.76

Estimate

$0.76

Surprise

+132.2%

Score today

5.1/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

BioNTech (BNTX) beat the $0.76 estimate with adjusted EPS of $1.76 — a large 132.2% upside surprise.

• BioNTech Q3 2026 Earnings Call Transcript — benzinga, 2026-11-03
• BioNTech Says Trastuzumab Pamirtecan Benefit Likely Limited In HR+/HER2-Low Breast Cancer; Discussing BLA Plans With Dua — benzinga, 2026-11-03
• BioNTech: Phase 3 DYNASTY-Breast02 Of Trastuzumab Pamirtecan Met PFS Endpoint, But Improvement Modest With Higher Rate O — benzinga, 2026-11-03

TrendMatrix currently rates BNTX Sell at 5.1/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +132.2% surprise compares with a +23.3% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$86.92

Price target

$105.58

Stop

$82.45

Upside to target

+21.5%

Reward-to-risk

3.8:1

Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$21.83B

P/E (fwd)

-15.9

52-week range

$79.52–$124.00

Off 52-week high

29.9%

RSI (14)

45

Volume vs avg

1.01×

Score today

5.1/10